The South San Francisco-based startup Nodality has raised $15.5 million in venture funds to finance its work developing new diagnostic tests designed to match cancer patients with the right therapies. Launched with the help of Kleiner Perkins Caufield & Byers, this new round joins the flagship fund for disruptive technologies with the venture arm of Pfizer.
Nodality is run by David Parkinson, who had been in charge of oncology R&D at Biogen Idec until the fall of 2007. Parkinson had also completed stints at Amgen and Novartis, where he helped advance some of the leading cancer drugs in use today. Nodality's tests characterize cell signaling pathways in defined cellular sub-populations of malignant and normal cells.
"We continue to focus on meeting our near-term commercial timelines, developing new tests, and expanding the market potential of Single Cell Network Profiling which we believe provides the opportunity to greatly improve patient care and outcomes as well as the drug development process," said Parkinson in a prepared statement.
Pfizer Ventures led the round with Laboratory Corporation of America Holdings. Kleiner Perkins Caulfield & Byers, TPG Biotechnology, and Maverick Capital all joined in.
- check out Nodality's release for more info